Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - lamotrigine, quantity: 200 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; aspartame; hyprolose; purified talc; colloidal anhydrous silica; magnesium stearate; maltodextrin; calcium carbonate; flavour - noumed lamotrigine is an antiepileptic drug for the treatment of partial and generalized seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - lamotrigine, quantity: 100 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; aspartame; hyprolose; purified talc; colloidal anhydrous silica; magnesium stearate; calcium carbonate; maltodextrin; flavour - noumed lamotrigine is an antiepileptic drug for the treatment of partial and generalized seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - lamotrigine, quantity: 50 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; aspartame; hyprolose; purified talc; colloidal anhydrous silica; magnesium stearate; calcium carbonate; maltodextrin; flavour - noumed lamotrigine is an antiepileptic drug for the treatment of partial and generalized seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - lamotrigine, quantity: 25 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; aspartame; hyprolose; purified talc; colloidal anhydrous silica; magnesium stearate; calcium carbonate; maltodextrin; flavour - noumed lamotrigine is an antiepileptic drug for the treatment of partial and generalized seizures in adults and children. there is extensive experience with lamotrigine used initially as "add-on" therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs. initial monotherapy treatment in newly diagnosed paediatric patients is not recommended.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - simvastatin, quantity: 40 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; citric acid monohydrate; lactose monohydrate; purified talc; ascorbic acid; hypromellose; pregelatinised maize starch; butylated hydroxyanisole; titanium dioxide; iron oxide red; magnesium stearate - adjunct to diet for treatment of hypercholesterolaemia.prior to initiating therapy with noumed simvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. noumed simvastatin is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris.these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - simvastatin, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; iron oxide yellow; titanium dioxide; citric acid monohydrate; purified talc; ascorbic acid; lactose monohydrate; hypromellose; microcrystalline cellulose; pregelatinised maize starch; iron oxide red; butylated hydroxyanisole - adjunct to diet for treatment of hypercholesterolaemia.prior to initiating therapy with noumed simvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. noumed simvastatin is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris.these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - simvastatin, quantity: 10 mg - tablet, film coated - excipient ingredients: citric acid monohydrate; lactose monohydrate; titanium dioxide; ascorbic acid; hypromellose; purified talc; microcrystalline cellulose; iron oxide yellow; pregelatinised maize starch; iron oxide red; magnesium stearate; butylated hydroxyanisole - adjunct to diet for treatment of hypercholesterolaemia.prior to initiating therapy with noumed simvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. noumed simvastatin is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris.these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 111.9 mg (equivalent: sertraline, qty 100 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; calcium hydrogen phosphate dihydrate; purified talc; hypromellose; magnesium stearate; microcrystalline cellulose; hyprolose; titanium dioxide - treatment of children (aged 6 years and older) and adolescents with obsessive compulsive disorder. treatment of major depression, obsessive compulsive disorder and panic disorder in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - sertraline hydrochloride, quantity: 55.95 mg (equivalent: sertraline, qty 50 mg) - tablet, film coated - excipient ingredients: titanium dioxide; calcium hydrogen phosphate dihydrate; purified talc; microcrystalline cellulose; hypromellose; hyprolose; sodium starch glycollate; magnesium stearate - treatment of children (aged 6 years and older) and adolescents with obsessive compulsive disorder. treatment of major depression, obsessive compulsive disorder and panic disorder in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - sildenafil citrate, quantity: 140.4 mg (equivalent: sildenafil, qty 100 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; copovidone; croscarmellose sodium; saccharin sodium; indigo carmine aluminium lake; calcium hydrogen phosphate; magnesium stearate - noumed sildenafil is indicated for the treatment of erectile dysfunction in adult males. noumed sildenafil is not indicated for use by women.